NextCure, Inc. - NXTC
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Squadron Master Fund LP | 1.6% | 64,464 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Squadron Capital Management LLC | 1.6% | 64,464 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Matthew Sesterhenn | 1.6% | 64,464 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | William Blank | 1.6% | 64,464 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 6.4% | 274,073 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Michael Cho | 6.4% | 274,073 | View |
| Aug 12, 2026 | SCHEDULE 13G | Adage Capital Management, L.P. | 7.67% | 277,202 | View |
| Aug 12, 2026 | SCHEDULE 13G | Robert Atchinson | 7.67% | 277,202 | View |
| Aug 12, 2026 | SCHEDULE 13G | Phillip Gross | 7.67% | 277,202 | View |
| May 13, 2026 | SCHEDULE 13G/A | SilverArc Capital Management, LLC | 4.9% | 176,057 | View |
| May 13, 2026 | SCHEDULE 13G/A | Devesh Gandhi | 4.9% | 176,057 | View |
| May 06, 2026 | SCHEDULE 13G/A | Simcere Zaiming, Inc. | 9.4% | 338,636 | View |
| May 06, 2026 | SCHEDULE 13G/A | Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | 9.4% | 338,636 | View |
| May 06, 2026 | SCHEDULE 13G/A | Simcere Zaiming Pharmaceutical Co., Ltd. | 9.4% | 338,636 | View |
| May 06, 2026 | SCHEDULE 13G/A | Simcere Pharmaceutical Group Limited | 9.4% | 338,636 | View |
| May 06, 2026 | SCHEDULE 13G/A | Ren Jinsheng | 9.4% | 338,636 | View |
| May 06, 2026 | SCHEDULE 13G/A | Tang Renhong | 9.4% | 338,636 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.